8 completed, 5 recruiting, 4 unknown, 3 terminated. 6 Phase 1, 6 Phase 2, 2 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow EBV: new trials by email Literature Review of EBV trials Research Report on EBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults VXCO-102, Placebo - EBV | Phase 1 | Recruiting | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 82 | 2026-11-16 | 2026-10-26 |
| Golidocitinib Combined With Selinexor for CAEBVD golidocitinib, Selinexor (combination therapy) - Lymphohistiocytosis, EBV | Phase 2 / Phase 3 | Recruiting | Beijing Friendship Hospital | 28 | 2026-01-01 | 2026-01-27 |
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant - EBV, Epstein-Barr Virus Infection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 750 | 2025-05-29 | 2026-10-26 |
| KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial KSD-101 - Nasopharyngeal Carcinoma (NPC), EBV | Early Phase 1 | Not yet recruiting | Kousai Bio Co., Ltd. | 10 | 2025-01-31 | 2024-12-30 |
| A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT NCR300（Allogenic Ipsc-derived Natural Killer cells ） - CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV | Not applicable | Unknown | Beijing Friendship Hospital | 15 | 2024-07-15 | 2024-07-11 |
| Response Prediction in EBV-HLH Using Metabonomics Analysis observational - Hemophagocytic Lymphohistiocytoses, EBV | Unknown | Beijing Friendship Hospital | 30 | 2023-01-01 | 2023-01-10 | |
| Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults EBV gp350-Ferritin Vaccine - EBV, Epstein-Barr Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 83 | 2022-03-29 | 2026-08-13 |
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. PD-1 antibody (SHR-1210) - Gastric Cancer Stage IV, EBV | Phase 2 | Completed | Sun Yat-sen University | 6 | 2018-12-01 | 2022-09-21 |
| Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial Valaciclovir, Placebo capsules (containing Avicel blend) - COPD, EBV | Phase 2 | Terminated | Belfast Health and Social Care Trust | 85 | 2018-10-11 | 2020-09-30 |
| Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Chidamide BIW, Chidamide QD - Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | Unknown | Huiqiang Huang | 24 | 2016-09-01 | 2016-08-25 |
| Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis Serological giagnosis - EBV | Completed | Centre Hospitalier Universitaire, Amiens | 91 | 2015-01-01 | 2026-06-16 | |
| A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® IFN-γ positive selected T-cells - Adenovirus Infection, EBV | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 30 | 2014-12-01 | 2025-03-20 |
| Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma baltaleucel-T - Lymphoma, Extranodal NK-T-Cell, EBV | Phase 2 | Terminated | Cell Medica Ltd | 15 | 2014-09-01 | 2019-03-13 |
| Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Nelfinavir - Non-Hodgkin Lymphoma, Hodgkin Lymphoma | Early Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2014-07-01 | 2016-06-10 |
| Belatacept 3 Month Post Transplant Conversion Study belatacept, Tacrolimus, MPA - Transplant; Failure, Kidney, EBV | Phase 4 | Completed | Lorenzo Gallon | 28 | 2014-07-01 | 2023-02-08 |
| CNTRP POSITIVE Study Transplant, Adaptive Immunity | Completed | The Hospital for Sick Children | 600 | 2014-04-01 | 2021-10-08 | |
| Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) CTL for CMV seropositive donors, CTL for CMV naïve donors - EBV, CMV | Phase 1 | Completed | Catherine Bollard | 27 | 2014-02-01 | 2025-07-03 |
| Cytotoxic T Cells to Prevent Virus Infections Cytotoxic T lymphocytes (CTLs). - CMV, EBV | Phase 1 | Completed | Children's National Research Institute | 10 | 2013-09-01 | 2020-07-14 |
| Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Virus specific CTLs - CMV Infection, EBV | Phase 1 | Unknown | University of Sydney | 25 | 2013-01-01 | 2016-07-21 |
| Plasma EBV DNA Monitoring in Post-treatment NPC Patients Nasopharyngeal Carcinoma, NPC | Completed | Taichung Veterans General Hospital | 441 | 2011-08-01 | 2019-06-07 |
Showing 20 of 21. Sign in to see all of them.
Adenoviridae Infections (5) · Epstein-Barr Virus Infections (5) · Infectious Mononucleosis (3) · Cytomegalovirus Infections (2) · Lymphohistiocytosis, Hemophagocytic (2) · Lymphoma, Extranodal NK-T-Cell (2) · Nasopharyngeal Carcinoma (2) · Stomach Neoplasms (2) · Castleman Disease (1) · Herpes Simplex (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Medication Adherence (1)
DNA Virus Infections (11) · Infections (11) · Virus Diseases (10) · Herpesviridae Infections (9) · Hemic and Lymphatic Diseases (6) · Lymphatic Diseases (6) · Immune System Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Tumor Virus Infections (5) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Neoplasms by Site (4) · Head and Neck Neoplasms (3) · Hematologic Diseases (3)
Abatacept (1) · Combined Modality Therapy (1) · Mycophenolic Acid (1) · Nelfinavir (1) · Tacrolimus (1) · Valacyclovir (1) · Watchful Waiting (1) · camrelizumab (1) · selinexor (1)
Beijing Friendship Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Belfast Health and Social Care Trust (1) · Catherine Bollard (1) · Cell Medica Ltd (1) · Centre Hospitalier Universitaire, Amiens (1) · Children's National Research Institute (1) · Huiqiang Huang (1) · Kousai Bio Co., Ltd. (1) · Lorenzo Gallon (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1) · Taichung Veterans General Hospital (1) · The Hospital for Sick Children (1) · University Hospital, Basel, Switzerland (1)
United States (8) · China (4) · Australia (2) · France (2) · United Kingdom (2) · Canada (1) · South Korea (1) · Switzerland (1) · Taiwan (1)
Jessica R Durkee-Shock, M.D. (3) · Catherine Bollard, MD (1) · Catherine M Bollard, M.D (1) · Helen Heslop, MD (1) · Jin-Ching Lin, M.D.,PhD (1) · Joe Kidney, MB, MD (1) · Kurt Gunter, MD (1) · Lorenzo Gallon, MD (1) · Nina Khanna, Dr. (1) · Richard Ambinder, MD (1) · Rui-Hua Xu, MD, PhD (1) · Sandrine Castelain, MD, PhD (1) · Seema Mital, MD (1) · Zhao Wang, MD (1)
PMID 29296867, PMID 31219185, PMID 33755393, PMID 34339090, PMID 34765307, PMID 36740715, PMID 37011709, PMID 42311676